Biogen’s sales for its new Alzheimer’s drug fell short of Wall Street expectations, with the drugmaker reporting on Wednesday that it brought in millions less than anticipated from aduhelm in the third quarter.The first Alzheimer’s drug approved by…
Source: The Hill
Sales of new Alzheimer's drug fall short of expectations
More from Make America Late AgainMore posts in Make America Late Again »
- How U.S. Gas Gives Options to Europe but Increases Pollution Back Home
- “Jus Ex Bello” and the Continued Justice of Ukraine’s Fight Against Russia
- Making Global Ethics More Global
- Psaki, Jean-Pierre absences give others possible at White House audition
- The Memo: Border surge spells trouble for Biden, Democrats
Be First to Comment